By Delilah Alvarado
Published September 10, 2026
In a significant blow to its late-stage pipeline, Biohaven announced this week that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its development program for opakalim, also known as BHV-7000. The regulatory intervention arrives just weeks after Biohaven finalized a high-stakes licensing deal for the drug, casting a shadow over the company’s recent efforts to stabilize its financial footing and restore investor confidence.
The halt specifically impacts the enrollment of patients in the RISE-2 study—a trial that many industry analysts view as a pivotal component in the eventual regulatory submission for the treatment of focal epilepsy. While Biohaven maintains that the drug has been well-tolerated in over 1,200 patients to date, the FDA’s decision reflects an ongoing caution regarding the drug’s metabolic profile.
A Chronology of Turbulence: The Biohaven Narrative
To understand the weight of the current hold, one must look at the unconventional history of the company. Biohaven is effectively the "second act" of a biotech success story. The original entity, known for its breakthrough migraine therapy, was acquired by Pfizer in 2022. Following that acquisition, the leadership team immediately reconstituted under the Biohaven name, taking with them a portfolio of experimental medicines targeting a diverse range of neurological and rare diseases.
However, the second iteration of Biohaven has struggled to replicate the singular focus and clinical success of its predecessor. The company’s trajectory has been marked by a series of high-profile setbacks:
- Regulatory Rejections: The company’s candidate for spinocerebellar ataxia, Vyglyxia (troriluzole), faced a controversial rejection by the FDA, leading to a significant loss of market valuation.
- Pipeline Failures: Biohaven’s attempt to enter the spinal muscular atrophy (SMA) market ended in a trial failure, while separate efforts to address depression with other assets also fell short of efficacy endpoints.
- Operational Shifts: In response to these headwinds, the company has undergone multiple restructuring phases, including the drastic slashing of research and development costs, a turnover in scientific leadership, and a pivot toward leaner operations to preserve dwindling cash reserves.
Opakalim: A High-Stakes Pivot
Opakalim (BHV-7000) represents a central pillar in Biohaven’s current strategy. Though the drug failed to meet primary endpoints in a Phase 2 proof-of-concept study for major depressive disorder earlier this year, the company pivoted, reframing the asset as a next-generation, selective treatment for focal epilepsy and a potential candidate for chronic pain management.
The strategic importance of opakalim was underscored last month when Biohaven entered into a licensing agreement with South Korea’s SK Biopharmaceuticals. The deal, valued at up to $795 million, was designed to inject much-needed capital into the company. By trading away a portion of the long-term upside, Biohaven secured an immediate $350 million payment—a move that William Blair analyst Minter described as "prudent but necessary" given the company’s cash burn rate.
Supporting Data and the Regulatory Question
At the heart of the FDA’s partial hold is a concern regarding a specific metabolite associated with the drug. According to regulatory filings, the FDA is requesting additional data to fully characterize this metabolite’s profile.
Biohaven has taken a defensive posture, asserting in a regulatory filing that it maintained full transparency with SK Biopharmaceuticals regarding all clinical and nonclinical data prior to the finalization of the licensing deal. This disclosure suggests that the leadership at SK was aware of the regulatory risks associated with the metabolite and remained comfortable proceeding with the partnership.
Despite the halt, Biohaven remains optimistic about the drug’s safety profile. The company reports that in the 1,200 patients dosed across its development programs, opakalim has shown a consistent safety signal, with no major adverse events that would inherently disqualify the drug from further testing. However, "tolerability" in a controlled environment is only one aspect of the regulatory hurdle; the FDA’s demand for additional clarity signals that they require a more granular understanding of how the body processes the drug over longer durations.
The Implications for Investors and Patients
The halt on the RISE-2 study introduces a layer of uncertainty that the market is clearly struggling to price. For a company that has already weathered significant volatility, the delay in the RISE-2 readout is a critical inflection point.
Analyst Perspectives
- Leonid Timashev (RBC Capital Markets): Timashev has highlighted the potential for a prolonged delay, noting that the data currently requested by the FDA is likely "ultimately necessary for an approval." He further warned that the requirement for additional data adds significant binary risk to the program, as any new testing could inadvertently uncover a "concerning signal" that was not captured in earlier, smaller cohorts.
- Market Impact: The immediate effect has been one of skepticism. While the SK Biopharmaceuticals deal provided a liquidity bridge, the FDA hold suggests that the "easy money" phase of the company’s turnaround is over. Investors are now forced to weigh the potential of the drug against the increased probability of a lengthy and costly regulatory battle.
Clinical Implications
For patients suffering from focal epilepsy, the development of a selective treatment is a high-priority medical need. Current standard-of-care treatments often come with heavy side-effect profiles, and a drug like opakalim, which promises higher selectivity, could be a transformative option. However, the path to market for such drugs is narrow. The FDA is historically conservative when it comes to new, novel mechanisms of action, and any sign of metabolic instability typically triggers a "stop-and-look" response.
Conclusion: A Path Forward?
The coming months will be defining for Biohaven. To lift the partial clinical hold, the company must work closely with the FDA to design a plan that satisfies the agency’s data requirements regarding the flagged metabolite.
If Biohaven can provide the requested data without identifying new safety signals, the program may resume with only a moderate delay. However, if the FDA determines that further long-term animal or human studies are required to characterize the metabolite, the timeline for a New Drug Application (NDA) will shift significantly.
For a company that has already faced the gauntlet of drug development failures, the opakalim program is no longer just a promising asset—it is a barometer for the company’s survival. With the $350 million from the SK deal providing a runway, Biohaven has the resources to address these regulatory hurdles. Whether they have the clinical data to satisfy the FDA remains the multi-million dollar question.
As the industry watches, the focus will remain on the dialogue between Biohaven’s scientists and the regulators in White Oak, Maryland. The outcome of these discussions will determine whether opakalim becomes the cornerstone of Biohaven’s rebirth or another chapter in a series of disappointments.
